Moneycontrol PRO

Buy SRF; target of Rs 2,800: Sharekhan

Sharekhan is bullish on SRF has recommended buy on the stock with a revised price target (PT) of Rs. 2,800 in its research report dated January 27, 2022.

January 28, 2022 / 09:22 PM IST

SRF Limited’s Q3FY22 results were above our estimates with 8.6%/9.6% beat in revenue/operating profit at Rs. 3,346 crore/Rs. 881 crore, up 55.9%/55.7% y-o-y. Better-than-expected operational performance was driven by: 1) robust growth in chemical segment (revenue/EBIT margin up by 57.7%/839 bps y-o-y) led by strong demand / pricing environment for ref-gas in international market, positive contribution from Chloromethanes and healthy performance from specialty chemical business and 2) sharp sequential recovery in packaging film segment (revenues rose 59.1%/19.1% y-o-y/q-o-q and improvement in EBIT margin by 317 bps q-o-q to 19.9%) supported by improved BOPET/BOPP spreads. However, the technical textiles division’s performance was a tad lower than our expectations with revenue decline of 3.6% q-o-q and margin contraction by 270 bps q-o-q to 21.1% (although per unit margin remained stable), reflecting weak demand for Nylon Tyre Cord Fabrics. PAT at Rs. 506 crore (up 55.9% y-o-y; up 32.2% q-o-q) was in-line our estimate of Rs. 505 crore as a beat in operating profit was offset by higher depreciation and tax rate at 30.8% (versus assumption of 25.2%).


High growth in the chemical business supported by high capex intensity, sustained strong margin for the technical textiles business and focus on value-added products (VAP) in the packaging film business would drive strong revenue/EBITDA/PAT CAGR of 23%/23%/28% over FY2021- FY2024E and a healthy RoE/RoCE of 21.6%/23.5%. Investment in right areas of specialty chemical business would improve earnings quality and safeguard from cyclical packaging film margins. A superior earnings growth outlook, strong FCF generation and robust balance sheet keep us constructive on SRF and justify its premium valuations. Hence, we maintain a Buy on SRF with a revised PT of Rs. 2,800 reflecting upward revision in earnings on higher growth/margin assumption in chemical business. At CMP, the stock is trading at 34.3x its FY2023E EPS and 27.6x its FY2024E EPS.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Jan 28, 2022 09:22 pm